Journal of Jilin University(Medicine Edition) ›› 2026, Vol. 52 ›› Issue (2): 469-482.doi: 10.13481/j.1671-587X.20260219

• Research in clinical medicine • Previous Articles    

Expression of GSTO1 in ovarian cancer tissue and effect of N-glycosylation site mutations on biological behaviors of epithelial ovarian cancer cells

Hong LI1,2,Panpan YU2,Zouyu ZHAO1,2,Chongfeng SUN1,2,Hui QIAO1,2,Ping YANG1,2,3()   

  1. 1.Department of Gynecology,First Affiliated Hospital,Shihezi University,Shihezi 832008,China
    2.School of Medicine,Shihezi University,Shihezi 832008,China
    3.Department of Gynecology,Xinjiang Production and Construction Corps Hospital,Urumqi 830001,China
  • Received:2025-04-25 Accepted:2025-07-06 Online:2026-03-28 Published:2026-04-15
  • Contact: Ping YANG E-mail:pingy2018@163.com

Abstract:

Objective To discuss the expression of glutathione S-transferase Omega-1 protein (GSTO1) in epithelial ovarian cancer (EOC) tissue and its relationship with the clinicopathological characteristics and prognosis of the patients, and to investigate the effect of its N-glycosylation modification on the biological behaviors of ovarian cancer A2780 and SKOV3 cells, and to clarify its possible mechanism. Methods GENT2 database was used to analyze the expression levels of GSTO1 mRNA in ovarian cancer tissue and normal ovarian epithelial tissue. The clinical information of 88 EOC patients who visited and underwent surgery in the Department of Gynecology of the First Affiliated Hospital of Shihezi University was collected, the tissue samples were collected, and the prognosis of the patients was followed up regularly. Immunohistochemical method was used to detect the expression of GSTO1 protein in ovarian tissue of EOC patients, and its relationship with the clinicopathological characteristics and prognosis of the patients was analyzed. Univariate and multivariate Cox regression analyses were used to evaluate the risk factors affecting the prognosis of EOC patients. Mass spectrometry was used to compare the difference in N-glycosylation modification of GSTO1 protein between highly metastatic ovarian cancer ES-2 cells and parental SKOV3 cells, and NetNGlyc 1.0 server database was used to identify its modification sites. Tunicamycin was used to inhibit the overall N-glycosylation of cells, and ovarian cancer A2780 and SKOV3 cells were divided into control group, dimethyl sulfoxide (DMSO) group, and tunicamycin group. The ovarian cancer A2780 and SKOV3 cells with different levels of N-glycosylation modification were stably constructed by lentiviral transfection and divided into NC group, WT group, N55Q group, N135Q group, N190Q group, and N3Q group. 5-Ethynyl-2'-deoxyuridine (EdU) assay was used to detect the proliferation rates of the cells in various groups; Transwell chamber assay was used to detect the numbers of migration cells and invasion cells in various groups; Western blotting method was used to detect the expression levels of GSTO1 protein and epithelial-mesenchymal transition (EMT)-related proteins E-cadherin, N-cadherin, and Vimentin in the cells in various groups. Results According to GENT2 database, compared with normal ovarian epithelial tissue, the expression level of GSTO1 mRNA in ovarian cancer tissue was significantly increased (P<0.01). Immunohistochemical staining results showed that there were 66 cases with high expression of GSTO1 and 22 cases with low expression of GSTO1 in tumor tissues of EOC patients.The high expression of GSTO1 protein in tumor tissue of EOC patients was associated with FIGO stage, lymphovascular space invasion, and tumor diameter (P<0.05). The univariate and multivariate Cox regression analyses results showed that high FIGO stage, lymph node metastasis, and high GSTO1 expression were independent risk factors affecting the overall survival (OS) and progression-free survival (PFS) of EOC patients. The mass spectrometry results showed that compared with parental SKOV3 cells, the level of N-glycosylation modification of GSTO1 in highly metastatic ovarian cancer ES-2 cells was significantly increased (P<0.05), and its N-glycosylation modification sites were Asn55, Asn135, and Asn190, respectively. Compared with control group, the expression levels of GSTO1 protein in A2780 and SKOV3 cells in tunicamycin group were significantly decreased (P<0.05). Compared with WT group, the expression levels of GSTO1 protein in A2780 and SKOV3 cells in N135Q, N190Q, and N3Q groups were significantly decreased (P<0.05). Compared with WT group, the proliferation rates of A2780 and SKOV3 cells in N135Q, N190Q, and N3Q groups were significantly decreased (P<0.05). Compared with WT group, the numbers of migration cells and invasion cells of A2780 and SKOV3 cells in N55Q, N135Q, N190Q, and N3Q groups were significantly decreased (P<0.05). Compared with WT group, the expression levels of E-cadherin protein in A2780 and SKOV3 cells in N3Q group were significantly increased (P<0.05), and the expression levels of N-cadherin protein and Vimentin protein in A2780 and SKOV3 cells in N190Q and N3Q groups were significantly decreased (P<0.05). Conclusion GSTO1is highly expressed in EOC tissue and cells and is associated with poor prognosis of patients. Mutation of its N-glycosylation sites can inhibit the proliferation, migration, invasion, and EMT process of ovarian cancer cells.

Key words: Epithelial ovarian cancer, Glutathione S-transferase Omega-1 protein, N-glycosylation, Cell migration, Cell invasion, Cell proliferation, Epithelial-mesenchymal transition

CLC Number: 

  • R737.33